Back to top
more

Clovis Oncology, Inc. (CLVS)

(Delayed Data from NSDQ)

$18.95 USD

18.95
1,240,915

+0.51 (2.77%)

Updated May 3, 2019 04:00 PM ET

After-Market: $18.96 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Zacks.com featured highlights include Clovis Oncology, NiSource, DocuSign, Root and Endava

by Zacks Equity Research

Clovis Oncology, NiSource, DocuSign, Root and Endava are part of the Zacks Screen of the Week article.

Sanghamitra Saha headshot

Bet on 5 Top Stocks With Rising P/E

by Sanghamitra Saha

Forget undervalued stocks, play top-ranked stocks like Clovis Oncology (CLVS), NiSource (NI), DocuSign (DOCU), Root (ROOT) and Endava (DAVA).

Clovis (CLVS) Files for Bankruptcy Amid Lack of Financial Aid

by Zacks Equity Research

Recent regulatory developments force Clovis (CLVS) to file for bankruptcy. The company inks a stalking horse agreement with Novartis for one of its pipeline candidates.

Clovis (CLVS) Down 18.1% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Clovis (CLVS) Stock Down 50% in the Past 6 Months: Here's Why

by Zacks Equity Research

Clovis Oncology (CLVS) tanks in the past six months following the possibility of a bankruptcy filing in the near term.

Down 67.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Clovis (CLVS)

by Zacks Equity Research

Clovis (CLVS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Clovis (CLVS) Plummets on News of Possible Bankruptcy Filing

by Zacks Equity Research

Clovis (CLVS) tanks following the possibility of a bankruptcy filing in the near term after recent regulatory developments impacted current revenues and the commercial potential of Rubraca.

Clovis Oncology (CLVS) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Clovis (CLVS) delivered earnings and revenue surprises of 7.14% and 11.87%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Guardant Health (GH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Guardant Health (GH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Clovis Oncology (CLVS) Report Negative Q3 Earnings? What You Should Know

by Zacks Equity Research

Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Clovis (CLVS) Seeks Nod for Rubraca in First Line Ovarian Cancer

by Zacks Equity Research

Clovis (CLVS) files regulatory applications in the United States and Europe seeking label expansion for its sole marketed drug as a first-line maintenance treatment in advanced ovarian cancer.

Clovis (CLVS) Down 12.6% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Clovis (CLVS) Q2 Loss Wider Than Expected, Revenues Miss

by Zacks Equity Research

Clovis (CLVS) incurs a wider-than-estimated loss in second-quarter 2022. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts. CLVS faces the risk of a cash crunch.

Clovis Oncology (CLVS) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Clovis (CLVS) delivered earnings and revenue surprises of -2.38% and 15.01%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Will Clene Inc. (CLNN) Report Negative Q2 Earnings? What You Should Know

by Zacks Equity Research

Clene Inc. (CLNN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Clovis Oncology (CLVS) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Clovis (CLVS) Up 19.4% on Upbeat Data From Solid Tumor Study

by Zacks Equity Research

Clovis Oncology (CLVS) reports favorable data from a study, which supports the potential clinical utility of FAP-2286, its targeted radiotherapy candidate, as a treatment for advanced solid tumors.

Why Is Clovis (CLVS) Down 55.2% Since Last Earnings Report?

by Zacks Equity Research

Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Viatris' (VTRS) Q1 Earnings Beat, Revenues Miss Estimates

by Zacks Equity Research

Viatris (VTRS) beats on Q1 earnings but misses sales estimates. The company is on track to close its biosimilars deal with Biocon Biologics in the second half.

Alcon (ALC) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Strength in Vision Care with the addition of new products and recent acquisition is likely to have contributed to Alcon's (ALC) first-quarter performance.

Endo (ENDP) Beats on Q1 Earnings, Guides Weak Q2 Results

by Zacks Equity Research

Endo (ENDP) tops Q1 earnings and sales estimates. However, Vasostrict faces generic competition and the guidance for Q2 is dismal.

STERIS (STE) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Strength in Healthcare and AST arms is expected to have driven STERIS' (STE) fourth-quarter revenues.

Global Blood (GBT) Q1 Loss Narrower Than Expected, Revenues Lag

by Zacks Equity Research

Global Blood Therapeutics (GBT) reports y/y wider loss in Q1. Revenues witness a rise.

Clovis (CLVS) Q1 Loss Wider than Expected, Revenues Miss

by Zacks Equity Research

Clovis (CLVS) incurs wider-than-estimated loss for first-quarter 2022. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts.

Clovis Oncology (CLVS) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Clovis (CLVS) delivered earnings and revenue surprises of -2.33% and 7.52%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?